Renal Osteodystrophy

OVERVIEW OF RENAL OSTEODYSTROPHY

• Definition: Refers to bone morphology alterations found in patients with chronic kidney disease (CKD).
• Common Forms:
  1. High bone turnover due to secondary or tertiary hyperparathyroidism (HPT), including osteitis fibrosa cystica
  2. Low bone turnover with adynamic bone disease
  3. Low bone turnover combined with increased unmineralized bone (osteomalacia)
  4. β₂-microglobulin–associated amyloid deposits forming bone cysts
  5. Mixed osteodystrophy with both high- and low-turnover elements

TWO KEY PATHOLOGIC FACTORS IN CKD

1. Decreased Renal Conversion of 25(OH)D → 1,25(OH)₂D (calcitriol)
2. Decreased Ability to Excrete Inorganic Phosphate (Pi)

SECONDARY HYPERPARATHYROIDISM (HPT)

• As GFR decreases, the filtered load of phosphate falls → serum phosphate rises → serum calcium (Ca²⁺) drops → PTH increases (secondary HPT).
• Also, reduced 1,25(OH)₂D production (due to decreased renal mass) → less calcium absorbed from gut → further PTH rise.
• Although initially PTH partially corrects these abnormalities (by lowering phosphate reabsorption, raising bone resorption of calcium, and boosting calcitriol), over time it becomes maladaptive as kidney function worsens.

TERTIARY HYPERPARATHYROIDISM

• Definition: Refractory hypersecretion of PTH with severe parathyroid hyperplasia or neoplastic transformation (monoclonal adenomas).
• Pathophysiology:
  • Failing kidneys can’t excrete phosphate despite high PTH → continued bone resorption elevates both calcium + phosphate → hypercalcemia → metastatic calcification (soft tissues, joints, arteries) → can cause ischemia, gangrene.
• Bone Findings: Subperiosteal resorption, cysts, osteitis fibrosa cystica (brown tumors), fractures, “salt-and-pepper” skull, “band” vertebral sclerosis.

ADYNAMIC BONE DISEASE

• Most common in dialysis patients (peritoneal or hemodialysis).
• Low bone turnover, absence of bone cell activity → no osteoid formation increase (unlike osteomalacia).
• Associated with excess PTH suppression (e.g., due to calcium-based phosphate binders and vitamin D analogues).
• Clinical: Raises fracture risk (e.g., hip fractures).
• Biochemical Clue: Often serum PTH <100 pg/mL.
• Key Management: Allow PTH to rise by reducing or discontinuing calcium-based binders / vitamin D analogues.

OSTEOMALACIA (WITH RENAL FAILURE)

• Pathophysiology: Decreased bone turnover + excess unmineralized bone, from vitamin D deficiency or aluminum intoxication.
• Radiographic Findings:
  • Looser zones (pseudofractures) = narrow radiolucent lines, perpendicular to cortex, with sclerotic borders; bilateral and symmetric.
  • Bone resorption at lateral clavicle ends.
  • Milkman syndrome = bilateral symmetric pseudofractures in osteomalacia.
• Fractures: Minimal or no trauma, commonly in long bones (e.g., hip), ribs, vertebrae.
• Diagnostic: Bone biopsy after tetracycline labeling can confirm decreased mineralization.

OTHER FACTORS CONTRIBUTING TO BONE DISEASE IN CKD

• Vitamin K deficiency (needed for bone matrix protein carboxylation).
• Bone morphogenetic protein-7 deficiency (kidney normally produces BMP-7 to aid osteoblast differentiation).

TREATMENT APPROACHES

1. Normalize serum Ca²⁺ and phosphate levels while minimizing aluminum.
2. Dietary phosphate restriction plus phosphate binders if GFR <25% normal.
3. Vitamin D supplementation to maintain normal 1,25(OH)₂D levels.
4. Parathyroidectomy for tertiary HPT or intractable secondary HPT with severe hypercalcemia / bone disease.